Alzheimer disease and cerebrovascular pathology: an update
The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Recent epidemiological and clinico-pathologic data suggest overlaps between Alzheimer disease (AD) and cerebrovascular lesions that may magnify the effect of mild AD pathology and promote progression of cognitive decline or even may precede neuronal damage and dementia. Vascular pathology in the aging brain and in AD includes: 1. cerebral amyloid angiopathy (CAA) with an incidence of 82-98% often associated with ApoE epsilon 2 and causing a) cerebral mass hemorrhages (around 70%, mainly in the frontal and parietal lobes), b) multiple or recurrent microhemorrhages (15%), and c) ischemic (micro-)infarcts or lacunes (around 20%). The frequency of these lesions increases with the severity of CAA and shows no correlation with that of senile amyloid plaques. CAA, significantly more frequent in patients with cerebral hemorrhages or infarcts than in aged controls, is an important risk factor for cerebrovascular lesions in AD. 2. Microvascular changes with decreased density and structural abnormalities causing regional metabolic and blood-brain barrier dysfunctions with ensuing neuronal damage. In large autopsy series of demented aged subjects, around 80% show Alzheimer type pathology, 20-40% with additional, often minor vascular lesions, 7-10% "pure" vascular dementia, and 3-5% "mixed" dementia (combination of AD and vascular encephalopathy). AD cases with additional minor cerebrovascular lesions have significantly more frequent histories of hypertension or infarcts than "pure" AD patients. Vascular lesions in AD include cortical microinfarcts, subcortical lacunes, white matter lesions / leukoencephalopathy, small hemorrhages and corticosubcortical infarcts, while in mixed type dementia multiple larger or hemispheral infarcts are more frequent. Small infarcts in AD patients have no essential impact on global cognitive decline which mainly depends on the severity of Alzheimer pathology, but in early stage of AD they may influence and promote the development of dementia. Recent studies showed lower density of plaques and tangles in brains with cerebrovascular lesions, and similar severity of dementia was related to fewer AD lesions in brains with than in those without small vascular lesions. Further studies will help to elucidate the risk factors and impact of cerebrovascular lesions on the development and progression of dementia in AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CAA appears in ≈10% to 30% of unselected brain autopsies and 80% to 100% when in the presence of accompanying Alzheimer disease.136”
In the citing paper
“which virtually all individuals with AD and about a third of aged cognitively normal individuals have) [68, 179]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [68]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“of currently used neuropathological diagnostic criteria for AD (Mirra et al., 1991; Braak and Braak, 1991; Hyman, 1998).”
BackgroundMethodMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Observations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084 · cited 2×
“…to many authors, MD should be diagnosed only if there are sufficient vascular and degenerative lesions to make each diagnosis independently (Tomlinson et al., 1970; Boller et al., 1989; Erkinjuntti, 1988; Jellinger et al., 1990; Mirra et al., 1991), while others suggest the diagnosis of AD…”
Background15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726 · cited 1×
“An association between hypertension and AD has been reported in several prospective studies (Skoog et al., 1993, 1996; Hofman et al., 1997; Skoog, 2000; Launer et al., 2000; Meyer et al., 2000; Schmidt et al., 2000; Kivipelto et al., 2001).”
BackgroundKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 2×
“An association between hypertension and AD has been reported in several prospective studies (Skoog et al., 1993, 1996; Hofman et al., 1997; Skoog, 2000; Launer et al., 2000; Meyer et al., 2000; Schmidt et al., 2000; Kivipelto et al., 2001).”
Background(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338 · cited 2×
“that came to autopsy, but most patients had mixed disease without clear thresholds of pathological features that predicted dementia (Esiri et al., 2001).”
BackgroundChui, H. C., Victoroff, J. I., Margolin, D., Jagust, W., Shankle, R., & Katzman, R. (1992) · Neurology · doi:10.1212/wnl.42.3.473 · Cited by 1,201 · cited 2×
“, 1991), while in the ADDTC criteria (Chui et al., 1992), a second cerebrovascular disorder in addition to AD must be shown to”
BackgroundCerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102 · cited 6×
“…vessels (Claudio, 1996; Farkas et al., 2000) with increase of collagen IV (Kalaria and Pax, 1995) and breakdown of the BBB are considered important factors for disturbances of cerebral metabolism, reduced cerebral blood flow and neural metabolic changes (Shi et al., 2000; Farkas and Luiten, 2001).”
BackgroundInfluentialHofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van Harskamp, F., van Duijn, C. N., Van Broeckhoven, C., & Grobbee, D. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09328-2 · Cited by 1,062 · cited 4×
“Hypertension and hypercholesterinemia, independent of the ApoE genotype have been shown to be risk factors for AD (Hofman et al., 1997; Skoog et al., 1999).”
BackgroundInfluentialClinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria
Knudsen, K. A., Rosand, J., Karluk, D., & Greenberg, S. M. (2001) · Neurology · doi:10.1212/wnl.56.4.537 · Cited by 1,015
Cited by
Items 101–200 of 681
Cardiovascular comorbidities, inflammation, and cerebral small vessel disease
Evans, L., Taylor, J. L., Smith, C. J., Pritchard, H. A. T., Greenstein, A. S., & Allan, S. M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab284 · Cited by 158
“cSVD increases with age and is noted in around 90% of Alzheimer’s disease (AD) patients.(16) Many studies also show that cSVD pathology”
BackgroundAlzheimer disease and risk of stroke: A population-based cohort study
Chi, N.-F., Chien, L.-N., Ku, H.-L., Hu, C.-J., & Chiou, H.-Y. (2013) · Neurology · doi:10.1212/wnl.0b013e31828250af · Cited by 125
Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124
“These effects of anti-A immunotherapy present a significant risk in light of the fact that CAA is associated with pathological abnormalities and cognitive impairment in the elderly population, and is prevalent in 80% of patients with AD (25, 26).”
BackgroundThe effect of white matter lesions on cognition in the elderly—small but detectable
Frisoni, G. B., Galluzzi, S., Pantoni, L., & Filippi, M. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0638 · Cited by 133
Morris, A. W. J., Carare, R. O., Schreiber, S., & Hawkes, C. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00251 · Cited by 147
“CAA is observed in 30–40% of non-demented elderly individuals and 60–95% of AD brains studied at autopsy (Vinters, 1987; Castano and Frangione, 1988; Haan et al., 1991; Jellinger, 2002).”
BackgroundCerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.76 · Cited by 122
4D flow MRI for intracranial hemodynamics assessment in Alzheimer’s disease
Rivera-Rivera, L. A., Turski, P., Johnson, K. M., Hoffman, C., Berman, S. E., Kilgas, P., Rowley, H. A., Carlsson, C. M., Johnson, S. C., & Wieben, O. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15617171 · Cited by 122
Causes and consequences of baseline cerebral blood flow reductions in Alzheimer’s disease
Bracko, O., Cruz Hernández, J. C., Park, L., Nishimura, N., & Schaffer, C. B. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20982383 · Cited by 124
Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study
Jellinger, K. A., & Attems, J. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0634-5 · Cited by 133
Self-citationCirculating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
The pathology of ischemic-vascular dementia
Jellinger, K. A. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00282-4 · Cited by 132
Self-citationAttems, J., Quass, M., Jellinger, K. A., & Lintner, F. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.013 · Cited by 140
Self-citationPosterior white matter disease distribution as a predictor of amyloid angiopathy
Thanprasertsuk, S., Martinez-Ramirez, S., Pontes-Neto, O. M., Ni, J., Ayres, A., Reed, A., Swords, K., Gurol, M. E., Greenberg, S. M., & Viswanathan, A. (2014) · Neurology · doi:10.1212/wnl.0000000000000732 · Cited by 120
“In addition, some degree of CAA frequently coexists with AD pathology.(25) Given these data, patients with lobar MBs from the memory clinic likely carry CAA.”
BackgroundDu, A., Schuff, N. W., Chao, L. L., Kornak, J., Ezekiel, F., Jagust, W. J., Kramer, J. H., Reed, B., Miller, B. L., Norman, D. M., et al. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.05.002 · Cited by 131
Hereditary Cerebral Hemorrhage With Amyloidosis Associated With the E693K Mutation of APP
Bugiani, O., Giaccone, G., Rossi, G., Mangieri, M., Capobianco, R., Morbin, M., Mazzoleni, G., Cupidi, C., Marcon, G., Giovagnoli, A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.178 · Cited by 117
“Most elderly people are asymptomatic carriers of A -CAA.(4,5) In AD patients, A CAA may contribute to cognitive impairment by adding vascular lesions to neurodegeneration.”
BackgroundAvila-Muñoz, E., & Arias, C. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.07.004 · Cited by 114
Nikolic, W. V., Hou, H., Town, T., Zhu, Y., Giunta, B., Sanberg, C. D., Zeng, J., Luo, D., Ehrhart, J., Mori, T., et al. (2008) · Stem Cells and Development · doi:10.1089/scd.2008.0018 · Cited by 113
“In addition to parenchymal A deposits, deposition of A in the cerebral vasculature (known as CAA) is a pathological feature of AD, and occurs with 83% frequency in AD patients [34,54–56].”
Intracellular pathways underlying the effects of lithium
Pasquali, L., Busceti, C. L., Fulceri, F., Paparelli, A., & Fornai, F. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833da5da · Cited by 112
“…the neuropathological hallmarks are the senile plaques, deposition of amyloid-b peptides in the neuropil (Jellinger and Bancher, 1998) and around blood vessels (Jellinger, 2002), and the intraneuronal neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau, a microtubule-binding protein.”
BackgroundLacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0340-8 · Cited by 111
“In addition, Aβ40 is the main component of amyloid deposition occurring in cerebral amyloid angiopathy (CAA) [14], which has a prevalence of about 80–90% in patients with AD [15].”
BackgroundManagement of Alzheimer's Disease
Grossberg, G. T., & Desai, A. K. (2003) · The Journals of Gerontology Series A · doi:10.1093/gerona/58.4.m331 · Cited by 118
“Recent epidemiological and clinicopathologic data suggest overlaps between AD and cerebrovascular lesions that may magnify the effects of mild AD pathology and promote progression of cognitive and functional decline (194).”
BackgroundProteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease
Roher, A. E., Maarouf, C. L., Sue, L. I., Hu, Y., Wilson, J., & Beach, T. G. (2009) · Biomarkers · doi:10.3109/13547500903108423 · Cited by 108
Cerebral amyloid angiopathy–associated intracerebral hemorrhage: pathology and management
Mehndiratta, P., Manjila, S., Ostergard, T., Eisele, S., Cohen, M. L., Sila, C., & Selman, W. R. (2012) · Neurosurgical Focus · doi:10.3171/2012.1.focus11370 · Cited by 108
Kövari, E., Herrmann, F. R., Hof, P. R., & Bouras, C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12003 · Cited by 105
Vascular and metabolic dysfunction in Alzheimer’s disease: a review
Murray, I. V. J., Proza, J. F., Sohrabji, F., & Lawler, J. M. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.010355 · Cited by 104
Lok, K., Hong, Z., Shen, H., Wang, Z., Gao, X., Zhao, W., & Yin, M. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.10.051 · Cited by 116
Clinical phenotypes of Cerebral Amyloid Angiopathy
Maia, L. F., Mackenzie, I. R., & Feldman, H. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.054 · Cited by 116
“It is not clear if in this context CAA is part of the normal aging process [3,7,18] or whether individuals were completely asymptomatic as these relationships are most often addressed retrospectively.”
BackgroundThe untwining of immunosenescence and aging
Xu, W., Wong, G. C. L., Hwang, Y. Y., & Larbi, A. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00824-x · Cited by 115
Resident tissue macrophages: Key coordinators of tissue homeostasis beyond immunity
Zhao, J., Andreev, I., & Silva, H. M. (2024) · Science Immunology · doi:10.1126/sciimmunol.add1967 · Cited by 101
“Brain PVMs likely play a role in other diseases—including cerebral amyloid angiopathy (CAA), a disorder characterized by amyloid accumulation on the walls of small blood vessels and a common cooccurrence in a spectrum of neurodegenerative diseases ( 171 ).”
BackgroundAgyare, E. K., Curran, G. L., Ramakrishnan, M., Yu, C. C., Poduslo, J. F., & Kandimalla, K. K. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9688-y · Cited by 104
Ossenkoppele, R., Iaccarino, L., Schonhaut, D. R., Brown, J. A., La Joie, R., O'Neil, J. P., Janabi, M., Baker, S. L., Kramer, J. H., Gorno-Tempini, M.-L., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101848 · Cited by 105
Aluminum complexing enhances amyloid β protein penetration of blood–brain barrier
Banks, W. A., Niehoff, M. L., Drago, D., & Zatta, P. F. (2006) · Brain Research · doi:10.1016/j.brainres.2006.07.112 · Cited by 119
Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia
Weekman, E. M., & Wilcock, D. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150759 · Cited by 106
Cerebral microbleeds and cognition in cerebrovascular disease: An update
Charidimou, A., & Werring, D. J. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.05.052 · Cited by 112
“In AD, CAA is almost invariable, being found at autopsy in more than 90% of cases [30,31], with severe CAA found in about onequarter [32].”
BackgroundCardiac Disorders as Risk Factors for Alzheimer's Disease
Alves, T. C. T. F., Ferreira, L. K., Wajngarten, M., & Busatto, G. F. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091561 · Cited by 114
“In very elderly subjects, selective hippocampal sclerosis may be accompanied by multiple other vascular pathologies [202,203].”
BackgroundThe Behavioral and Cognitive Neurology of Stroke
(2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544880 · Cited by 101
Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease
Canobbio, I., Abubaker, A. A., Visconte, C., Torti, M., & Pula, G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00065 · Cited by 112
“It has been suggested that vascular-restricted mesenchyme homeobox 2 gene (MEOX2) signaling is impaired in AD patients, which interferes with the process of angiogenesis (Jellinger, 2002; Paris et al., 2004; Wu et al., 2005).”
BackgroundThal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100
Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E., & Ikonomović, M. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 111
“%) in AD (for review see (Jellinger, 2002)).”
Suo, Z., Wu, M., Citron, B. A., Palazzo, R. E., & Festoff, B. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301406200 · Cited by 100
High Prevalence of Cerebral Microbleeds at 7Tesla MRI in Patients with Early Alzheimer's Disease
Brundel, M., Heringa, S. M., de Bresser, J., Koek, H. L., Zwanenburg, J. J. M., Kappelle, L. J., Luijten, P. R., & Biessels, G. J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120364 · Cited by 97
“[2, 3].”
The impact of cerebrovascular lesions in Alzheimer disease: A comparative autopsy study
Jellinger, K. A., & Mitter-Ferstl, E. (2003) · Journal of Neurology · doi:10.1007/s00415-003-0142-0 · Cited by 111
“7 % macroscopically showed accompanying CVLs (lacunes, hippocampal sclerosis, leukoencephalopathy, old or fresh infarcts, hemorrhages associated with cerebral amyloid angiopathy/CAA/, or mixed AD + vascular encephalopathy), the rest presenting with other additional pathologies [14].”
MethodInfluentialSelf-citationCognitive impairment in humanized APP×PS1 mice is linked to Aβ1–42 and NOX activation
Bruce-Keller, A. J., Gupta, S., Knight, A. G., Beckett, T. L., McMullen, J. M., Davis, P. R., Murphy, M. P., Van Eldik, L. J., St Clair, D., & Keller, J. N. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.012 · Cited by 96
“An important and primary pathological feature of AD is the progressive accumulation of amyloid β-protein (Aβ) into neuritic plaques (Jellinger, 2002), (Selkoe, 2001), (Vinters and Farag, 2003), (Walsh and Selkoe, 2004), and the progression of cognitive decline is associated with accumulation of Aβ…”
Rivera‐Rivera, L. A., Schubert, T. B., Turski, P. A., Johnson, K. M., Berman, S. E., Rowley, H. A., Carlsson, C. M., Johnson, S. C., & Wieben, O. E. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16661340 · Cited by 96
“One proposed mechanism by which pathologic changes of the cerebrovasculature might affect the evolution of the disease is an increase in pulsatility due to reduced vascular compliance, as has been reported in AD patients.(12,13) The brain may be especially vulnerable to increased arterial pulsatility due to the low re…”
BackgroundHernández‐Guillamón, M., Martínez-Sáez, E. A., Delgado, P., Domingues‐Montanari, S., Boada, C., Peñalba, A., Boada, M., Pagola, J., Maisterra, O., Rodríguez‐Luna, D., et al. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00512.x · Cited by 101
“In addition to the high incidence of CAA in Alzheimer’s disease (AD) (11), this disorder is clinically significant for being one of the main causes of symptomatic lobar intracerebral hemorrhage (ICH) in the elderly.”
BackgroundLi, J., Pan, P., Huang, R., & Shang, H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.001 · Cited by 100
Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias
Turner, R. S., Stubbs, T., Davies, D. A., & Albensi, B. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00496 · Cited by 94
Weinstock, M., & Shoham, S. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0058-y · Cited by 105
“White matter lesions and disorders of the BBB occur in SDAT as well as in vascular and mixed type dementias (Jellinger, 2002).”
BackgroundXu, F., Grande, A., Robinson, J. K., Previti, M. L., Vasek, M. J., Davis, J., & Nostrand, W. E. V. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.01.043 · Cited by 104
Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide
Casley, C. S., Lakics, V., Lee, H., Broad, L. M., Day, T. A., Cluett, T. J., Smith, M. A., O’Neill, M. J., & Kingston, A. E. (2009) · Brain Research · doi:10.1016/j.brainres.2008.12.082 · Cited by 101
Chong, J. R., Ashton, N. J., Karikari, T. K., Tanaka, T., Saridin, F. N., Reilhac, A., Robins, E. G., Nai, Y., Vrooman, H. A., Hilal, S., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12332 · Cited by 102
“Education, y, mean (SD) 10 (5) 8 (5) 5 (5)*# 5 (4)* <.”
Chuang, J., Lee, C.-W., Shih, Y., Yang, T., Yu, L., & Kuo, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033120 · Cited by 100
“linosis), microinfarcts, subcortial lacunes and micro-hemorrhages, are known to disturb the integrity of cerebral vessels and alter brain perfusion [51–54].”
BackgroundAquaporin expression in the cerebral cortex is increased at early stages of Alzheimer disease
Pérez, E., Barrachina, M., Rodríguez, A., Torrejón-Escribano, B., Boada, M., Hernández, I., Sánchez, M., & Ferrer, I. (2006) · Brain Research · doi:10.1016/j.brainres.2006.09.109 · Cited by 90
Blood-Cerebrospinal Fluid Barrier Permeability in Alzheimer's Disease
Chalbot, S., Zetterberg, H., Blennow, K., Fladby, T., Andreasen, N., Grundke-Iqbal, I., & Iqbal, K. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101959 · Cited by 88
Mechanism of Neuronal versus Endothelial Cell Uptake of Alzheimer's Disease Amyloid β Protein
Kandimalla, K. K., Scott, O. G., Fulzele, S., Davidson, M. W., & Poduslo, J. F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004627 · Cited by 88
“Alongside the parenchymal amyloid plaques, AD patients exhibit vascular amyloid deposits to varying extent [11].”
Neural stem cell therapy for neurovascular injury in Alzheimer's disease
Boese, A. C., Hamblin, M. H., & Lee, J. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113112 · Cited by 92
Tian, J., Shi, J., Bailey, K., & Mann, D. M. A. (2004) · Neuropathology and Applied Neurobiology · doi:10.1046/j.0305-1846.2003.00510.x · Cited by 89
The Pathophysiology and Clinical Presentation of Cerebral Amyloid Angiopathy
Auriel, E., & Greenberg, S. M. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0254-z · Cited by 95
Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia
Abrahamson, E. E., & Ikonomovic, M. D. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113257 · Cited by 86
Attems, J., Lauda, F., & Jellinger, K. A. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0674-4 · Cited by 105
“Spontaneous ICH (macroscopically detectable) were found in 5.6 % of the total cohort, and in 7.2 % of definite AD cases, which was similar to previous autopsy studies in AD [ 23 , 27], but lower than 16.7 % ICH among 600 autopsies of demented elderly subjects [24], and another personal study [26a].”
BackgroundResultInfluentialSelf-citationUnderstanding the pathology of vascular cognitive impairment
Jellinger, K. A. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.11.029 · Cited by 94
Self-citationChoi, B.-R., Lee, S. R., Han, J.-S., Woo, S.-K., Kim, K. M., Choi, D.-H., Kwon, K. J., Han, S.-H., Shin, C. Y., Lee, J., et al. (2011) · Stroke · doi:10.1161/strokeaha.111.620179 · Cited by 86
Kirshner, H. S., & Bradshaw, M. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0572-y · Cited by 86
Ithapu, V., Singh, V., Lindner, C., Austin, B. P., Hinrichs, C., Carlsson, C. M., Bendlin, B. B., & Johnson, S. C. (2014) · Human Brain Mapping · doi:10.1002/hbm.22472 · Cited by 85
“Their presence in the context of AD, particularly when cognitive symptoms are mild, is variable and their relative contribution to explaining the mechanism of cognitive loss in AD remains unclear [Brickman et al., 2012; Jellinger, 2002].”
BackgroundSvedberg, M. M., Hall, H., Hellström‐Lindahl, E., Estrada, S., Guan, Z.-Z., Nordberg, A. K., & Långström, B. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.016 · Cited by 93
Farid, K., Charidimou, A., & Baron, J. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.05.002 · Cited by 95
“In Alzheimer's disease brains, any degree of CAA is identified in a high proportion of cases (85–95%) when sought thoroughly, often involving, at times even preferentially, the capillaries (Jellinger, 2002; Kalaria and Ballard, 1999).”
BackgroundHuang, C.-W., Tsai, M.-H., Chen, N.-C., Chen, W.-H., Lu, Y.-T., Lui, C.-C., Chang, Y.-T., Chang, W.-N., Chang, A. Y. W., & Chang, C.-C. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0938 · Cited by 82
“In AD, a β-amyloid pathology often coexists in the vascular wall which becomes more densely packed as the disease progresses, and this may lead to worsened endothelial dysfunction (50).”
BackgroundImaging of cerebrovascular pathology in animal models of Alzheimer's disease
Klohs, J., Rudin, M., Shimshek, D. R., & Beckmann, N. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00032 · Cited by 82
“Among all cerebrovascular comorbidities in AD, cerebral amyloid angiopathy (CAA) is the most common pathological finding, present in up to 90% of AD patients (Vinters, 1987; Jellinger, 2002).”
BackgroundMetabolic Syndrome, Mild Cognitive Impairment and Dementia
Panza, F., Frisardi, V., Seripa, D., P. Imbimbo, B., Sancarlo, D., D'Onofrio, G., Addante, F., Paris, F., Pilotto, A., & Solfrizzi, V. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391818 · Cited by 79
Circulating beta amyloid protein is elevated in patients with acute ischemic stroke
Lee, P. H., Bang, O. Y., Hwang, E. M., Lee, J. S., Joo, U. S., Mook‐Jung, I., & Huh, K. H. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0274-0 · Cited by 87
“…characterized by the cerebrovascular deposition of Ab1–40 and is an important cause of cerebrovascular disorders including lobar cerebral hemorrhage as well as cognitive impairment (Jellinger, 2002; Nicoll et al., 2004), although origin of Ab deposited in cerebral vessels remains to be determined.”
BackgroundAutoantibody-catalyzed Hydrolysis of Amyloid β Peptide
Taguchi, H., Planque, S. A., Nishiyama, Y., Symersky, J., Boivin, S., Szabo, P., Friedland, R. P., Ramsland, P. A., Edmundson, A. B., Weksler, M. E., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707983200 · Cited by 86
Qi, X.-M., & Ma, J. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0091-7 · Cited by 92
“In addition, CAA is commonly found in Alzheimer’s disease (AD) and nearly 80% of AD patients are accompanied by CAA [4].”
BackgroundMurine models of Alzheimer's disease and their use in developing immunotherapies
Wısnıewskı, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 90
“This is an important issue since CAA is present in virtually all AD cases, with approximately 20% of AD patients having “severe” CAA [97].”
BackgroundAmyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders
Batarseh, Y., Duong, Q.-V., Mousa, Y., Al Rihani, S., Elfakhri, K., & Kaddoumi, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030338 · Cited by 79
“As a detectable pathology, cerebrovascular amyloid is present in approximately 10% to 40% of elderly brains and 80% or more in brains of AD patients [81].”
BackgroundDivecha, Y. A., Rampes, S., Tromp, S., Boyanova, S., Fleckney, A. L., Fidanboylu, M., & Thomas, S. A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100052 · Cited by 92
“From brain autopsy, CAA has been found in 30% e 40% of elderly individuals without dementia and 60% e 95% of patients with AD (Vinters, 1987; Prelli et al, 1988; Haan et al, 1991; Jellinger, 2002).”
Cerebral microbleeds and risk of incident dementia: the Framingham Heart Study
Romero, J. R., Beiser, A., Himali, J. J., Shoamanesh, A., DeCarli, C. S., & Seshadri, S. S. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.018 · Cited by 86
“(Jellinger, 2002, Rensink et al., 2003, Toledoet al., 2013) In prior cross-sectional studies and selected samples CMB have been associated with risk of prevalent dementia.”
BackgroundErkinjuntti, T., Kurz, A., Small, G. W., Bullock, R. A., Lilienfeld, S., & Damaraju, C. V. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80168-6 · Cited by 79
Liao, F., Zhang, T. J., Jiang, H., Lefton, K. B., Robinson, G. O., Vassar, R., Sullivan, P. M., & Holtzman, D. M. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0250-y · Cited by 77
“The vast majority of patients diagnosed with AD also have cerebral amyloid angiopathy (CAA), deposition of Aβ on the cerebral vessels [16].”
Robert, J., Stukas, S. K., Button, E. B., Cheng, W. H., Lee, M., Fan, J., Wilkinson, A., Kulić, I., Wright, S. D., & Wellington, C. L. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.005 · Cited by 98
Neurovascular Alterations in Vascular Dementia: Emphasis on Risk Factors
Lecordier, S., Manrique‐Castano, D., Moghrabi, Y. E., & ElAli, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.727590 · Cited by 80
“CAA affects 50–60% of the elderly population affected by dementia, including 85–95% of AD cases (Sacco, 2000; Jellinger, 2002; Thal et al., 2003; Keage et al., 2009; Charidimou et al., 2017; Zhang et al., 2017; Li et al., 2018).”
BackgroundChen, K., Kazachkov, M., & Yu, P. H. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0697-5 · Cited by 76
“Both oxidative stress and vascular disorders, such as diabetes mellitus are risk factors for Alzheimer’s disease ( Jellinger, 2002 ).”
BackgroundCerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage
Pezzini, A., Del Zotto, E., Volonghi, I., Giossi, A., Costa, P., & Padovani, A. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788682047 · Cited by 76
“Estimates for the proportion of spontaneous hemorrhages in the elderly that are due to CAA range from 10% to 20% in autopsy series [16] to 34% in clinical series [19].”
Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease
Benedictus, M. R., Goos, J. D. C., Binnewijzend, M. A. A., Muller, M., Barkhof, F., Scheltens, P., Prins, N. D., & van der Flier, W. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.023 · Cited by 85
“At autopsy, CAA is found in 80% to 95% of the AD cases (Jellinger, 2002).”
Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics
Jani, M., Temesszentandrási‐Ambrus, C., Magnan, R., Jakab, K. T., Beéry, E., Zolnerciks, J. K., & Krajcsi, P. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1224-8 · Cited by 86
“The deposited Abeta bundles are toxic to neurons (Oddo et al. 2013) and endothelial cells (Jellinger 2002).”
BackgroundA New Paradigm for the Treatment of Alzheimer's Disease: Targeting Vascular Activation
Grammas, P., Martinez, J. M., Sanchez, A. C., Yin, X., Riley, J., Gay, D., Desobry, K., Tripathy, D., Luo, J., Evola, M., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-2014-132057 · Cited by 77
Ahmadi, N., Safari, S., Mirazi, N., Karimi, S. A., & Komaki, A. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.02.024 · Cited by 74
The Role of Cholesterol Metabolism in Alzheimer’s Disease
Sun, J.-H., Yu, J.-T., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8749-y · Cited by 70
The Pathogenic Aβ43 Is Enriched in Familial and Sporadic Alzheimer Disease
Sandebring, A., Welander, H., Winblad, B., Graff, C., & Tjernberg, L. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055847 · Cited by 69
“[43,44].”
Omtri, R. S., Davidson, M. W., Arumugam, B., Poduslo, J. F., & Kandimalla, K. K. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200530q · Cited by 79
Bales, K. R., O’Neill, S. M., Pozdnyakov, N., Pan, F., Caouette, D., Pi, Y., Wood, K. M., Volfson, D., Cirrito, J. R., Han, B.-H., et al. (2016) · Brain · doi:10.1093/brain/awv313 · Cited by 68
“…CAA is almost always evident in brain tissue from subjects with sporadic late onset Alzheimer's disease and also contributes to other brain injuries such as ischaemic stroke and intracerebral haemorrhage (Jellinger, 2002; Weller and Nicoll, 2003; Kimberly et al., 2009; Garcia-Alloza et al., 2011).”
Banerjee, G., Jang, H., Kim, H. J., Kim, S. T., Kim, J. S., Lee, J. H., Im, K., Kwon, H., Lee, J. M., Na, D. L., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170943 · Cited by 69
Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage
Lee, J.-M., Yin, K., Hsin, I., Chen, S., Fryer, J. D., Holtzman, D. M., Hsu, C. Y., & Xu, J. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.11.041 · Cited by 67
Development of the Endothelium: An Emphasis on Heterogeneity
Dyer, L., & Patterson, C. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1253446 · Cited by 76
“The vascular changes are due to both amyloid b–induced vascular dysfunction and reduced neuronal processing, and the degree of microvessel degeneration is related to amyloid plaque formation.(88,89) One potential connection between the vascular and neuronal biology is apolipoprotein E, which is involved in both athero…”
BackgroundAnti-Selectin Therapy for the Treatment of Inflammatory Diseases
Rossi, B., & Constantin, G. (2008) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152808785107633 · Cited by 68
Gkanatsiou, E., Portelius, E., Toomey, C. E., Blennow, K., Zetterberg, H., Lashley, T., & Brinkmalm, G. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.033 · Cited by 72
Lee, G. D., Aruna, J. H., Barrett, P. M., Lei, D.-L., Ingram, D. K., & Mouton, P. R. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2004.11.024 · Cited by 68
Gonzalez‐Velasquez, F. J., Kotarek, J. A., & Moss, M. A. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05618.x · Cited by 65
Beckmann, N., Gérard, C., Abramowski, D., Cannet, C., & Staufenbiel, M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4936-10.2011 · Cited by 66
“At autopsy, 80% of the AD patients exhibit cerebral amyloid angiopathy (CAA) (Jellinger, 2002; Greenberg et al., 2004), characterized by deposition of A in the walls of cerebral vessels.”
BackgroundYagami, T., Ueda, K., Sakaeda, T., Itoh, N., Sakaguchi, G., Okamura, N., Hori, Y., & Fujimoto, M. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.11.005 · Cited by 65
Westmark, C. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.122 · Cited by 74
Poduslo, J. F., Hultman, K. L., Curran, G. L., Preboske, G. M., Chamberlain, R., Marjańska, M., Garwood, M., Jack, C. R., & Wengenack, T. M. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318225038c · Cited by 64
“Cerebrovascular amyloid (CVA) deposits are found in approximately 90% of patients with Alzheimer disease (AD), as well as sporadically in 30% of the population older than 60 years (1, 2).”
Metadata
- Authors
- Jellinger, K. A.
- Affiliations
- Ludwig Boltzmann für Klinische Neurobiologie (AT)
- Corresponding author
- Jellinger, K. A.
- ORCID
- Jellinger, K. A.
- Venue
- Journal of Neural Transmission
- Published
- 2002-05-01
- Volume
- 109
- Issue
- 5-6
- Pages
- 813-836
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2084675121
- Cited by
- 680
- References
- 114
- Citations by year
- 2026: 7 · 2025: 25 · 2024: 32 · 2023: 19 · 2022: 38 · 2021: 32 · 2020: 22 · 2019: 26 · 2018: 23 · 2017: 22 · 2016: 30 · 2015: 44 · 2014: 38 · 2013: 27 · 2012: 39
- FWCI
- 14.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, cerebrovascular pathology, cerebral amyloid angiopathy, cerebral hemorrhage, microinfarcts, lacunes, white matter lesions, mixed dementia, vascular dementia, cognitive decline, dementia progression, blood-brain barrier dysfunction
- MeSH terms
- Alzheimer Disease, Blood Vessels, Cerebrovascular Circulation, Cerebrovascular Disorders, Diagnosis, Differential, Humans, Microcirculation, Risk Factors, Dementia, Vascular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.